Cytotoksiske CD44-antistoff-immunokonjugater

The present invention relates to novel conjugates of antibodies with cytotoxic compounds, pharmaceutical compositions containing such conjugates, and their use in cancer therapy. In particular, the present invention relates to conjugates of antibodies which are specific for CD44 with maytansinods, p...

Full description

Saved in:
Bibliographic Details
Main Authors HEIDER, KARL-HEINZ, ADOLF, GUENTHER, PATZELT, ERIK, SPROLL, MARLIES
Format Patent
LanguageNorwegian
Published 17.11.2003
Edition7
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to novel conjugates of antibodies with cytotoxic compounds, pharmaceutical compositions containing such conjugates, and their use in cancer therapy. In particular, the present invention relates to conjugates of antibodies which are specific for CD44 with maytansinods, preferably with N<2'>-deacetyl-N<2'>-(3-mercapto-1-oxopropyl)-maytansine. In a particularly preferred embodiment, the antibody/maytansinoid conjugate may be prepared from a maytansinoid of formula wherein R1 represents H or SR4, wherein R4 represents methyl, ethyl, linear alkyl, branched alkyl, cyclic alkyl, simple or substituted aryl, or heterocyclic; R2 represents Cl or H; R3 represents H or CH3; and m represents 1,2, or 3. Preferably, R1 is H or CH3, R2 is Cl, R3 is CH3, and m=2. The compound with R1=H, R2=Cl, R3=CH3, and m=2 is designated DM1 in the literature.
Bibliography:Application Number: NO20030005108